Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Cost of Revenue (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Cost of Revenue data on record, last reported at $48.9 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 351.49% year-over-year to $48.9 million; the TTM value through Dec 2025 reached $53.9 million, up 122.38%, while the annual FY2025 figure was $53.9 million, 29.65% up from the prior year.
  • Cost of Revenue reached $48.9 million in Q4 2025 per OCUL's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $48.9 million in Q4 2025 and bottomed at -$18.1 million in Q4 2023.
  • Average Cost of Revenue over 5 years is $6.6 million, with a median of $1.9 million recorded in 2025.
  • Peak YoY movement for Cost of Revenue: soared 887.3% in 2021, then plummeted 1887.06% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $23.6 million in 2021, then plummeted by 95.72% to $1.0 million in 2022, then tumbled by 1887.06% to -$18.1 million in 2023, then surged by 159.94% to $10.8 million in 2024, then surged by 351.49% to $48.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $48.9 million in Q4 2025, $1.8 million in Q3 2025, and $1.9 million in Q2 2025.